Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

The HTLV-1 proviral status is a potential prognostic biomarker for adult T-cell leukemia-lymphoma treated with allogeneic stem cell transplantation

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Get just this article for as long as you need it


Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Overall survival and ATL-related deaths in the ATL-NST trials.


  1. Cook LB, Fuji S, Hermine O, Bazarbachi A, Ramos JC, Ratner L, et al. Revised adult t-cell leukemia-lymphoma international consensus meeting report. J Clin Oncol. 2019;37:677–87. e-pub ahead of print 2019/01/19

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Kanda J, Hishizawa M, Utsunomiya A, Taniguchi S, Eto T, Moriuchi Y, et al. Impact of graft-versus-host disease on outcomes after allogeneic hematopoietic cell transplantation for adult T-cell leukemia: a retrospective cohort study. Blood. 2012;119:2141–8. e-pub ahead of print 2012/01/12

    Article  CAS  PubMed  Google Scholar 

  3. Ishida T, Hishizawa M, Kato K, Tanosaki R, Fukuda T, Taniguchi S, et al. Allogeneic hematopoietic stem cell transplantation for adult T-cell leukemia-lymphoma with special emphasis on preconditioning regimen: a nationwide retrospective study. Blood. 2012;120:1734–41. e-pub ahead of print 2012/06/13

    Article  CAS  PubMed  Google Scholar 

  4. Fan J, Ma G, Nosaka K, Tanabe J, Satou Y, Koito A, et al. APOBEC3G generates nonsense mutations in human T-cell leukemia virus type 1 proviral genomes in vivo. J Virol. 2010;84:7278–87. e-pub ahead of print 2010/05/14

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Kannagi M, Hasegawa A, Takamori A, Kinpara S, Utsunomiya A. The roles of acquired and innate immunity in human T-cell leukemia virus type 1-mediated diseases. Front Microbiol. 2012;3:323. e-pub ahead of print 2012/09/13

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Jacobson S, Shida H, McFarlin DE, Fauci AS, Koenig S. Circulating CD8+ cytotoxic T lymphocytes specific for HTLV-I pX in patients with HTLV-I associated neurological disease. Nature. 1990;348:245–8. e-pub ahead of print 1990/11/15

    Article  CAS  PubMed  Google Scholar 

  7. Bazarbachi A, Cwynarski K, Boumendil A, Finel H, Fields P, Raj K, et al. Outcome of patients with HTLV-1-associated adult T-cell leukemia/lymphoma after SCT: a retrospective study by the EBMT LWP. Bone Marrow Transpl. 2014;49:1266–8. e-pub ahead of print 2014/07/17

    Article  CAS  Google Scholar 

  8. Shah NN, Waldmann TA. GVL for ATL? Blood. 2013;121:6–7. e-pub ahead of print 2013/01/05

    Article  CAS  PubMed  Google Scholar 

  9. Tamiya S, Matsuoka M, Etoh K, Watanabe T, Kamihira S, Yamaguchi K, et al. Two types of defective human T-lymphotropic virus type I provirus in adult T-cell leukemia. Blood. 1996;88:3065–73. e-pub ahead of print 1996/10/15

    Article  CAS  Google Scholar 

  10. Miyazaki M, Yasunaga J, Taniguchi Y, Tamiya S, Nakahata T, Matsuoka M. Preferential selection of human T-cell leukemia virus type 1 provirus lacking the 5’ long terminal repeat during oncogenesis. J Virol. 2007;81:5714–23. e-pub ahead of print 2007/03/09

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Inoue Y, Fuji S, Tanosaki R, Inamoto Y, Tanaka T, Ito A, et al. Prognostic importance of pretransplant disease status for posttransplant outcomes in patients with adult T cell leukemia/lymphoma. Bone Marrow Transpl. 2018;53:1105–15. e-pub ahead of print 2018/03/11

    Article  CAS  Google Scholar 

  12. Yamada K, Miyoshi H, Yoshida N, Shimono J, Sato K, Nakashima K, et al. Human T-cell lymphotropic virus HBZ and tax mRNA expression are associated with specific clinicopathological features in adult T-cell leukemia/lymphoma. Mod Pathol. 2021;34:314–26. e-pub ahead of print 2020/09/26

    Article  CAS  PubMed  Google Scholar 

Download references


We thank Dr. Linda Kingsbury for editorial comments and proofreading. This study was supported by the Ministry of Health Labour and Welfare (200300159A, 200622016B, 200925013B, and 201221027B to J-IY, IlC, YS, NU, JO, and MM), the Research Program on Emerging and Re-emerging Infectious Diseases (20fk0108088h0002 to J-IY and MM) from the Japan Agency for Medical Research and Development (AMED), and JSPS KAKENHI (19H03689 to MM and 20H03514 to J-IY). This study was also supported in part by the JSPS Core-to-Core Program A, Advanced Research Networks.

Author information

Authors and Affiliations



KT performed experiments; KT, JY, and IC, collected and analyzed the data; IC, YS, NU, and JO organized and conducted the ATL-NST trials, and collected the samples; KT, JY, and MM designed the research and wrote the manuscript; and all authors approved the final version of manuscript.

Corresponding author

Correspondence to Jun-ichirou Yasunaga.

Ethics declarations

Conflict of interest

The authors declare no competing interests.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Reprints and Permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Toyoda, K., Yasunaga, Ji., Choi, I. et al. The HTLV-1 proviral status is a potential prognostic biomarker for adult T-cell leukemia-lymphoma treated with allogeneic stem cell transplantation. Bone Marrow Transplant 56, 2027–2030 (2021).

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI:


Quick links